Epidiolex liver check: study tracks long-term injury risk
NCT ID NCT05044819
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 27 times
Summary
This study checks if long-term use of Epidiolex (cannabidiol) can cause liver damage or scarring in people with certain seizure disorders. It includes 154 participants who already take or will start Epidiolex for Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. Researchers will use blood tests and liver scans to monitor for fibrosis over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LENNOX GASTAUT SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Trial Site
Little Rock, Arkansas, 72758, United States
-
Clinical Trial Site
Downey, California, 90242, United States
-
Clinical Trial Site
Long Beach, California, 90806, United States
-
Clinical Trial Site
Sacramento, California, 95817, United States
-
Clinical Trial Site
Miami, Florida, 33136, United States
-
Clinical Trial Site
Miami, Florida, 33176, United States
-
Clinical Trial Site
Orlando, Florida, 32806, United States
-
Clinical Trial Site
Tampa, Florida, 33606, United States
-
Clinical Trial Site
Augusta, Georgia, 30912, United States
-
Clinical Trial Site
Wichita, Kansas, 67214, United States
-
Clinical Trial Site
Lexington, Kentucky, 40504, United States
-
Clinical Trial Site
Baltimore, Maryland, 21205, United States
-
Clinical Trial Site
Boston, Massachusetts, 02114, United States
-
Clinical Trial Site
New Brunswick, New Jersey, 08901, United States
-
Clinical Trial Site
New York, New York, 10016, United States
-
Clinical Trial Site
Charlotte, North Carolina, 28203, United States
-
Clinical Trial Site
Durham, North Carolina, 27708, United States
-
Clinical Trial Site
Cincinnati, Ohio, 45219, United States
-
Clinical Trial Site
Oklahoma City, Oklahoma, 73104, United States
-
Clinical Trial Site
Philadelphia, Pennsylvania, 19107, United States
-
Clinical Trial Site
Charleston, South Carolina, 29425, United States
-
Clinical Trial Site
Austin, Texas, 78758, United States
-
Clinical Trial Site
Dallas, Texas, 75251, United States
-
Clinical Trial Site
Houston, Texas, 77030, United States
-
Clinical Trial Site
Round Rock, Texas, 78681, United States
-
Clinical Trial Site
Winchester, Virginia, 22601, United States
Conditions
Explore the condition pages connected to this study.